Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Recurrent Venous thromboembolism
研究概览
简要总结
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients (≥18 years-of-age) with active cancer
- •Patient with at least one index venous thromboembolism (VTE )
- •≥6-months of continuous eligibility prior to the index VTE event (baseline period).
- •Newly initiated on rivaroxaban
排除标准
- •Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism (PE) during the 6 months pre-index date
- •Patients with prescription claim for anticoagulation therapy during the 6-month pre-index VTE period
研究组 & 干预措施
Cancer-associated thrombosis
Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
干预措施: Rivaroxaban (Xarelto, BAY59-7939) (Drug)
结局指标
主要结局
Recurrent Venous thromboembolism
时间窗: Retrospective analysis from November 2012 through September 2015
Derived using inpatient and outpatient medical claims
Bleeding (based on the Cunningham algorithm)
时间窗: Retrospective analysis from November 2012 through September 2015
Derived using inpatient and outpatient medical claims
Mortality (In-hospital mortality or need for hospice care without subsequent healthcare claims)
时间窗: Retrospective analysis from November 2012 through September 2015
Derived using inpatient and outpatient medical claims
次要结局
未报告次要终点